Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

Videos | Cardiovascular Ultrasound | July 10, 2018
DAIC Editor Dave Fornell highlights some of the most innovative new technology on the show floor of the...
Videos | Cardiovascular Ultrasound | July 03, 2018
Michael Lanspa, M.D., director of critical care echocardiography services, Intermountain Medical Center, Salt Lake Ci
Videos | Cardiovascular Ultrasound | July 02, 2018
Lissa Sugeng, M.D., associate professor of medicine, director of echocardiography and of the Yale Echo Core Lab, Yale
Videos | Cardiovascular Ultrasound | July 02, 2018
This is an example of the a mitral valve with regurgitation imaged with 3-D echocardiography using the Siemens SC2000
Videos | Cardiovascular Ultrasound | June 28, 2018
Sunil Mankad, M.D., FASE, ASE 2018 meeting program chair and director of transesophageal echocardiography at Mayo Cli
Videos | Cardiovascular Ultrasound | June 28, 2018
This is a demonstration of the the Philips TrueVue photo-realistic rendering and lighting source technology.
EchoMD AutoEF Software Improves Variability in Ejection Fraction Estimation
News | Cardiovascular Ultrasound | June 27, 2018
A recent study conducted with the Minneapolis Heart Institute found that Bay Labs’ EchoMD AutoEF deep learning software...
Epsilon Imaging Demonstrates Strain Imaging Integration for Echo Programs at ASE 2018
News | Cardiovascular Ultrasound | June 19, 2018
Clinical practice, along with guidelines and research, have shown that speckle tracking strain imaging can improve...
FDA Clears Bay Labs' EchoMD AutoEF Software for AI Echo Analysis
Technology | Cardiovascular Ultrasound | June 19, 2018
Cardiovascular imaging artificial intelligence (AI) company Bay Labs announced its EchoMD AutoEF software received 510(...
Videos | Cardiovascular Ultrasound | June 11, 2018
Thomas Porter, M.D., professor of medicine and director of the echocardiography lab at the University of Nebraska Med
Overlay Init